Systematic literature review of AbobotulinumtoxinA in clinical trials for lower limb spasticity

Medicine (United States)

Volumn 95, Issue 2, 2016, Pages

  Dashtipour, Khashayar ^a   Chen, Jack J ^a,b   Walker, Heather W ^c   Lee, Michael Y ^c  

^a LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MARSHALL B KETCHUM UNIVERSITY   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A;

ADULT; DOSE RESPONSE; DRUG ADMINISTRATION; FEMALE; FOLLOW UP; HUMAN; LOWER LIMB; MALE; MIDDLE AGED; MUSCLE SPASTICITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADULT; BOTULINUM TOXINS, TYPE A; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, SUBCUTANEOUS; LOWER EXTREMITY; MALE; MIDDLE AGED; MUSCLE SPASTICITY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84958205805     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000002468     Document Type: Article

References (23)

1. Pathak M, Truong D. Anatomic correlation of common patterns of spasticity. In: Brashear A, Elovic E, eds. Spasticity Diagnosis and Management. New York: Demos Medical; 2011.
2. Martin A, Abogunrin S, Kurth H, et al. Epidemiological, humanistic, and economic burden of illness of lower limb spasticity in adults: A systematic review. Neuropsychiatr Dis Treat. 2014;10: 111-122.
3. Hara Y. Deep venous thrombosis in stroke patients during rehabilitation phase. Keio J Med. 2008;57: 196-204.
4. Atiyeh BS, Hayek SN. Pressure sores with associated spasticity: A clinical challenge. Int Wound J. 2005;2: 77-80.
5. Royal College of Physicians, British Society of Rehabilitation Medicine, Chartered Society of Physiotherapy, Association of Chartered Physiotherapists Interested in Neurology. Spasticity in adults: Management using botulinum toxin. National guidelines. London: RCP, 2009.
6. Simpson DM, Gracies JM, Graham K, et al. Assessment: Botulinum neurotoxin for the treatment of spasticity (an evidence-based review). Neurology. 2009;73: 736-737author reply 737-738.
7. Wissel J, Ward AB, Erztgaard P, et al. European consensus table on the use of botulinum toxin type A in adult spasticity. J Rehabil Med. 2009;41: 13-25.
8. Dashtipour K, Chen JJ, Walker HW, et al. Systematic literature review of AbobotulinumtoxinA in clinical trials for adult upper limb spasticity. Am J Phys Med Rehabil. 2015;94: 229-238.
9. Des Jarlais DC, Lyles C, Crepaz N, et al. Improving the reporting quality of nonrandomized evaluations of behavioral and public health interventions: The TREND statement. Am J Public Health. 2004;94: 361-366.
10. Burbaud P, Wiart L, Dubos JL, et al. A randomised, double blind, placebo controlled trial of botulinum toxin in the treatment of spastic foot in hemiparetic patients. J Neurol Neurosurg Psychiatry. 1996;61: 265-269.
11. Hesse S, Jahnke MT, Luecke D, et al. Short-term electrical stimulation enhances the effectiveness of botulinum toxin in the treatment of lower limb spasticity in hemiparetic patients. Neurosci Lett. 1995;201: 37-40.
12. Johnson CA, Burridge JH, Strike PW, et al. The effect of combined use of botulinum toxin type A and functional electric stimulation in the treatment of spastic drop foot after stroke: A preliminary investigation. Arch Phys Med Rehabil. 2004;85: 902-909.
13. Pittock SJ, Moore AP, Hardiman O, et al. A double-blind randomised placebo-controlled evaluation of three doses of botulinum toxin type A (Dysport) in the treatment of spastic equinovarus deformity after stroke. Cerebrovasc Dis. 2003;15: 289-300.
14. Hyman N, Barnes M, Bhakta B, et al. Botulinum toxin (Dysport) treatment of hip adductor spasticity in multiple sclerosis: A prospective, randomised, double blind, placebo controlled, dose ranging study. J Neurol Neurosurg Psychiatry. 2000;68: 707-712.
15. Gusev Y, Banach M, Simonow A, et al. Efficacy and safety of botulinum type A toxin in adductor spasticity due to multiple sclerosis. J Musc Pain. 2008;16: 175-188.
16. Hubble J, Schwab J, Hubert C, et al. Dysport (botulinum toxin type A) in routine therapeutic usage: A telephone needs assessment survey of European physicians to evaluate current awareness and adherence to product labeling changes. Clin Neuropharmacol. 2013;36: 122-127.
17. Burridge JH, Wood DE, Hermens HJ, et al. Theoretical and methodological considerations in the measurement of spasticity. Disabil Rehabil. 2005;27: 69-80.
18. McIntyre A, Lee T, Janzen S, et al. Systematic review of the effectiveness of pharmacological interventions in the treatment of spasticity of the hemiparetic lower extremity more than six months post stroke. Top Stroke Rehabil. 2012;19: 479-490.
19. Bowden MG, Behrman AL. "Step activity monitor" accuracy and test-retest reliability in patients with incomplete spinal cord injury. J Rehabil Res Dev. 2007;44: 355-362.
20. Mudge S, Stott N. Test-retest reliability of the StepWatch activity monitor outputs in individuals with chronic stroke. Clin Rehabl. 2008;22: 871-877.
21. Subramony SH, Kedar S, Murray E, et al. Objective home-based gait assessment in spinocerebellar ataxia. J Neurol Sci 2012;313: 95-98.
22. Esquenazi A, Albanese A, Chancellor MB, et al. Evidence-based review and assessment of botulinum neurotoxin for the treatment of adult spasticity in the upper motor neuron syndrome. Toxicon. 2013;67: 115-128.
23. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011.